Astria Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATXS Nasdaq 2836 www.astriatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astria Therapeutics, Inc.

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - Jun 18th, 2025 6:00 am
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - Jun 13th, 2025 5:00 am
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress - Jun 6th, 2025 6:00 am
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 3rd, 2025 2:10 pm
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - May 28th, 2025 6:00 am
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop - May 23rd, 2025 6:00 am
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - May 22nd, 2025 6:00 am
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation - May 14th, 2025 9:00 am
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - May 13th, 2025 2:10 pm
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology - May 1st, 2025 6:00 am
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference - Apr 30th, 2025 6:00 am
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - Mar 11th, 2025 6:00 am
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema - Feb 27th, 2025 6:00 am
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference - Feb 25th, 2025 6:00 am
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Feb 22nd, 2025 6:01 am
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Feb 20th, 2025 6:00 am
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 4th, 2025 6:00 am
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session - Feb 3rd, 2025 6:00 am
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Jan 23rd, 2025 6:00 am
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - Jan 13th, 2025 6:00 am